GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD

儿童期后第二次恶性肿瘤的遗传倾向

• 批准号: 6278109
• 负责人: DEBRA L FRIEDMAN
• 金额: $ 2.4万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6278109
• 关键词: blood chemistry; genetic susceptibility; genotype; human genetic material tag; human subject; longitudinal human study; neoplasm /cancer genetics; neoplasm /cancer relapse /recurrence

This study is now open and to date 38 participants from The Children's Hospital of Philadelphia have been enrolled. Consent forms have been signed. Complete family histories have been obtained from these patients and I anticipate collection of blood samples for genotype testing to commence within the next month. Other cases of second malignancies and appropriate controls have been contacted for participation in the study and response is pending. In addition, I am continuing to receive updated information from the tumor registry regarding new cases who would meet eligibility requirements. Four such cases have been found to date and their participation in the study is being sought. Controls are being randomly chosen for these cases. With respect to the Childhood Cancer Cohort Study, a full proposal has been submitted and we expect participation of these study participants pending IRB and administrative approval at the local institutions. A mechanism has been established whereby the study participants are seen in the GCRC outpatient facility, or by their local physicians. The GCRC nurses will obtain blood samples locally or by mail and forward them to the GCRC laboratory where Dr. Friedman will work with the laboratory staff in DNA extraction and short cell culture preparation for RNA. The DNA/RNA will then be stored in the laboratory of Dr. Timothy Rebbeck and genotype testing will be performed in his and Dr. Weber's laboratories. Dr. Friedman has met with Dr. Rebbeck and his staff and has begun training in molecular biology techniques. She will develop additional assays for potential cancer susceptibility genes in the labs of Drs. Rebbeck and Weber. Bi-monthly meetings have been held with Dr. Meadows, the mentor for this project with respect to progress and potential areas of difficulty.

这项研究现已开放，迄今已有38名来自儿童基金会的参与者。 费城医院已入组。同意书已经 签署从这些患者中获得了完整的家族史 我预计会收集血样进行基因型检测， 下个月开始。 其他第二种恶性肿瘤病例和适当的对照已被 已联系参与研究的人员，正在等待答复。在 此外，我继续收到来自肿瘤的更新信息， 登记册上的新病例，谁将符合资格要求。四 到目前为止，已经发现了这种情况，他们参与研究的情况 被寻找。随机选择这些病例的对照组。 关于儿童癌症队列研究， 已提交，我们希望这些研究参与者参与 等待IRB和当地机构的行政批准。 已经建立了一个机制， 在GCRC门诊设施，或由他们的当地医生。GCRC 护士将在当地或通过邮寄方式获取血液样本，并将其转交给 弗里德曼博士将在GCRC实验室工作 在DNA提取和RNA的短细胞培养制备中的工作人员。的 然后，DNA/RNA将储存在蒂莫西·雷贝克博士的实验室， 基因型检测将在他和韦伯博士的实验室进行。 博士弗里德曼已经会见了雷贝克博士和他的工作人员， 分子生物学技术。她将开发更多的检测方法， 潜在的癌症易感基因在实验室里Rebeck博士和 韦伯每两个月与梅多斯博士举行一次会议，梅多斯博士是 这个项目的进展和潜在的困难领域。